Genetic Variants Associated With Cancer Therapy–Induced Cardiomyopathy
Pablo García‐Pavía(Universidad Francisco de Vitoria), Bonnie Ky(Washington Hospital), Zoltàn Arany(University of Pennsylvania), A. John Baksi(Royal Brompton & Harefield NHS Foundation Trust), Alicja Wilk(Royal Brompton & Harefield NHS Foundation Trust), Risha Govind(Royal Brompton & Harefield NHS Foundation Trust), Josep Lupón(Centro de Investigación Biomédica en Red), Antoni Bayés‐Genís(Universitat Autònoma de Barcelona), Alfredo Bardajı́(Institut de Recerca Biomèdica Catalunya Sud), Jonathan G. Seidman(Harvard University), Paul J.R. Barton(Guy's and St Thomas' NHS Foundation Trust), Parth Patel(Brigham and Women's Hospital), José Manuel García‐Pinilla(Centro de Investigación Biomédica en Red), Rachel Buchan(Guy's and St Thomas' NHS Foundation Trust), Erica Mazaika(Royal Brompton & Harefield NHS Foundation Trust), Upasana Tayal(Royal Brompton & Harefield NHS Foundation Trust), Richard Aplenc(University of Pennsylvania), Anjali Owens(University of Pennsylvania), Ida G. Lunde(University of Oslo), William Midwinter(Royal Brompton & Harefield NHS Foundation Trust), Fernándo Domínguez(Hospital Universitario Puerta de Hierro Majadahonda), Amanda M. Smith(University of Pennsylvania), Roddy Walsh(Royal Brompton Hospital), Hiroko Wakimoto(Harvard University), Beatriz Núñez(Hospital Universitario Puerta de Hierro Majadahonda), Steven R. DePalma(Harvard University), Alexander R. Lyon(Royal Brompton Hospital), Sanjay Prasad(Royal Brompton Hospital), Domingo A. Pascual‐Figal(Centro de Investigación Biomédica en Red), Declan P. O’Regan(MRC Clinical Trials Unit at UCL), Stuart D. Rosen(Royal Brompton & Harefield NHS Foundation Trust), Stuart A. Cook(Hammersmith Hospital), Antonio de Marvao(MRC Clinical Trials Unit at UCL), Kelly Getz(University of Pennsylvania), Jon A. L. Willcox(Harvard University), Christopher N. Toepfer(Harvard University), Enrique Lara‐Pezzi(Spanish National Centre for Cardiovascular Research), Brian S. Finkelman(University of Pennsylvania), Nicola Whiffin(Broad Institute), Mariano Provencio(Hospital Universitario Puerta de Hierro Majadahonda), María Alejandra Restrepo-Córdoba(Hospital Universitario Puerta de Hierro Majadahonda), Jian Li(Beijing Hospital), Yuri Kim(The University of Texas Southwestern Medical Center), Kaoru Ito(RIKEN Center for Integrative Medical Sciences), Isabel Serrano(Institut de Recerca Biomèdica Catalunya Sud), Antonis Pantazis(Harefield Hospital), Luis Alonso‐Pulpón(Hospital Universitario Puerta de Hierro Majadahonda), Nathan Ingold(Royal Brompton & Harefield NHS Foundation Trust), Mian Ahmad(Royal Brompton & Harefield NHS Foundation Trust), Joshua Gorham(Harvard University)
Cited by 344
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k